Tiapamil

Clinical data
Other names	Dimeditiapramine; Ro 11-1781
Identifiers
IUPAC name 2-(3,4-Dimethoxyphenyl)-2-(3-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}propyl)-1λ6,3λ6-dithiane-1,1,3,3-tetrone
CAS Number	57010-31-8 Y
PubChem CID	42107
ChemSpider	38399 N
UNII	0ONY823T4J
CompTox Dashboard (EPA)	DTXSID10205620
ECHA InfoCard	100.054.992
Chemical and physical data
Formula	C26H37NO8S2
Molar mass	555.70 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(CCCC1(S(=O)(=O)CCCS1(=O)=O)C2=CC(=C(C=C2)OC)OC)CCC3=CC(=C(C=C3)OC)OC

Tiapamil (INN; also known as dimeditiapramine) is a calcium antagonist or calcium channel blocker.^[1][2] It is an experimental drug that has never been marketed.^[3]

Tiapamil has been described as an antianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions include atrial fibrillation, atrial flutter, and super-ventricular tachycardia.^[4] Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensive verapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels. It can treat ventricular arrhythmias to a higher degree than traditional calcium antagonists.^{[medical citation needed]}

• Verapamil